ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 6, 2021

8:30AM-10:30AM: Abstract Number: 0017

Lessons Learnt from Associations Between Anti-modified Protein Antibodies and Risk Factors: Human Leukocyte Antigen – Shared Epitope Alleles Solely Associate with Anti-citrullinated Protein Antibodies

RA – Etiology & Pathogenesis Poster (0011–0045)

8:30AM-10:30AM: Abstract Number: 0060

Lipidomic Profiling Identifies Different Expression of Oxylipins Between Synovial Tissue and Plasma of Patients with Rheumatoid and Psoriatic Arthritis

Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)

8:30AM-10:30AM: Abstract Number: 0327

Lipoprotein(a) in Systemic Lupus Erythematosus Is Associated with History of Proteinuria and Renal Insufficiency

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

8:30AM-10:30AM: Abstract Number: 0410

Long-term Outcomes of Vascular Grafting of Medium Sized Vessels of the Wrist and Hand in Patients with Medication Refractory Systemic Sclerosis Related Raynaud’s Phenomenon at the University of Pennsylvania from 2009-2019

Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)

8:30AM-10:30AM: Abstract Number: 0245

Long-term Safety and Effectiveness of Abatacept Treatment in Patients with JIA: 5-year Results from the PRCSG/PRINTO JIA Real-World Registry

Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)

8:30AM-10:30AM: Abstract Number: 0190

Long-term Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – Interim Analysis of the RELIANCE Registry

Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)

8:30AM-10:30AM: Abstract Number: 0347

Longitudinal ANA Titers in SLE and ANA+ Controls

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

8:30AM-10:30AM: Abstract Number: 0418

Longitudinal Patterns of Renal Function in ANCA-Associated Vasculitis

Vasculitis – ANCA-Associated Poster (0414–0436)

8:30AM-10:30AM: Abstract Number: 0302

Loss of TAM Receptor Mer Contributes to Sjögren’s Syndrome–like Disease in Mice

Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)

8:30AM-10:30AM: Abstract Number: 0014

Low Baseline Expression of Pyruvate Kinase and Succinate Dehydrogenase Genes in the Peripheral Blood of Rheumatoid Arthritis Patients Treated with Tofacitinib Is Associated with Clinical Remission at the End of Follow-up

RA – Etiology & Pathogenesis Poster (0011–0045)

8:30AM-10:30AM: Abstract Number: 0309

Lymphopenia and Leukopenia in Sjogren Syndrome

Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)

8:30AM-10:30AM: Abstract Number: 0040

M1-M2 Polarization by CTLA4-Ig (Abatacept) on Cultured Circulating Monocytes from Rheumatoid Arthritis Patients and Healthy Subjects

RA – Etiology & Pathogenesis Poster (0011–0045)

8:30AM-10:30AM: Abstract Number: 0324

Machine Learning: Identifying Lupus Nephritis Within Systemic Lupus Erythematosus in the Real World

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

8:30AM-10:30AM: Abstract Number: 0246

Macrophage Activating Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Biological Drugs

Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)

8:30AM-10:30AM: Abstract Number: 0279

Macrophage Cholesterol Loading Associates with Low-density Lipoprotein Structure, Oxidation, Antibodies Against Oxidized Epitopes and Is Modified by Immunomodulatory Treatments in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].